Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Canderm** is a Shalina Healthcare topical dusting-powder formulation containing clotrimazole 1% w/w, an imidazole antifungal. It is marketed as an over-the-counter treatment for superficial fungal skin infections, including cutaneous candidiasis, tinea pedis, tinea cruris, tinea corporis, and pityriasis versicolor, and may be useful for moisture-aggravated intertriginous rashes. The registered product description also lists zinc oxide 1.75% w/w in the powder base; however, the product monograph identifies clotrimazole as the stated active pharmaceutical ingredient. ([greenbook.nafdac.gov.ng](https://greenbook.nafdac.gov.ng/products/details/4770))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Canderm.